Role of FDG-PET/CT in Prediction of Underestimation of Invasive Breast Cancer in Cases of Ductal Carcinoma In Situ Diagnosed at Needle Biopsy
Role of FDG-PET/CT in Prediction of Underestimation of Invasive Breast Cancer in Cases of Ductal Carcinoma In Situ Diagnosed at Needle Biopsy
复制标题
DOI：
10.1016/j.clbc.2014.04.006
复制
发表时间：
2014-10-01
影响因子：
3.1
通讯作者：
Okada, Morihito
中科院分区：
文献类型：
--
作者：
Shigematsu, Hideo;Kadoya, Takayuki;Okada, Morihito
四分之一的术前诊断为导管原位癌（DCIS）的患者在手术时会低估浸润性乳腺癌;因此，需要额外的腋窝淋巴结分期。这项研究已经证明，最大标准化摄取值（SUVmax）18氟-脱氧葡萄糖（FDG）-正电子发射断层扫描（PET）/计算机断层扫描（CT）是一个有用的预测指标为低估浸润性乳腺癌DCIS.Background：本研究的目的是评估的意义FDG-PET/CT预测低估浸润性乳腺癌的情况下，DCIS在针吸活检。患者和方法：在2010年至2013年期间接受根治性手术的83例在初次穿刺活检时诊断为DCIS的连续病例中，检查了切除前FDG-PET/CT上的SUVmax与低估浸润性乳腺癌之间的关系。结果：29例（34.9%）在手术切除时诊断为浸润性乳腺癌。受试者工作特征曲线分析显示SUVmax预测浸润性乳腺癌低估的临界值为1.6。SUVmax > 1.6的患者低估率为61.5%，SUVmax> 1.6的患者低估率为11.4
A quarter of patients with a preoperative diagnosis of ductal carcinoma in situ (DCIS) on needle biopsy specimens are subject to underestimation of invasive breast cancer at the time of the surgical procedure; consequently, additional axillary lymph node staging is required. This study has demonstrated that the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) is a useful predictive marker for the underestimation of invasive breast cancer in DCIS.Background: The aim of this study was to evaluate the significance of FDG-PET/CT for predicting the underestimation of invasive breast cancer in cases of DCIS at needle biopsy. Patients and Methods: Of 83 consecutive cases with diagnoses of DCIS at primary needle biopsy who underwent curative surgery between 2010 and 2013, the association between the SUVmax on FDG-PET/CT before excision and the underestimation of invasive breast cancer was examined. Results: There were 29 (34.9%) cases diagnosed to have invasive breast cancer at excision. Receiver operating characteristics curve analysis showed the cutoff value of the SUVmax to predict underestimation of invasive breast cancer was 1.6. The rates of underestimation were 61.5% for patients with a tumor of SUVmax > 1.6 and 11.4% for patients with a tumor of SUVmax